<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunha, César</style></author><author><style face="normal" font="default" size="100%">Garcia-Ureña, Mario</style></author><author><style face="normal" font="default" size="100%">Martínez, Raquel</style></author><author><style face="normal" font="default" size="100%">José Romero-Lado, María</style></author><author><style face="normal" font="default" size="100%">Fernandez, Maria Victoria</style></author><author><style face="normal" font="default" size="100%">Andreassen, Ole A.</style></author><author><style face="normal" font="default" size="100%">Sims, Rebecca</style></author><author><style face="normal" font="default" size="100%">Tsolaki, Magda</style></author><author><style face="normal" font="default" size="100%">Sleegers, Kristel</style></author><author><style face="normal" font="default" size="100%">Hiltunen, Mikko</style></author><author><style face="normal" font="default" size="100%">Nicolas, Gaël</style></author><author><style face="normal" font="default" size="100%">Sánchez-Juan, Pascual</style></author><author><style face="normal" font="default" size="100%">Ingelsson, Martin</style></author><author><style face="normal" font="default" size="100%">Giedraitis, Vilmantas</style></author><author><style face="normal" font="default" size="100%">Ghidoni, Roberta</style></author><author><style face="normal" font="default" size="100%">Holstege, Henne</style></author><author><style face="normal" font="default" size="100%">van Duijn, Cornelia</style></author><author><style face="normal" font="default" size="100%">van der Lee, Sven</style></author><author><style face="normal" font="default" size="100%">Ramirez, Alfredo</style></author><author><style face="normal" font="default" size="100%">Bellenguez, Céline</style></author><author><style face="normal" font="default" size="100%">Lambert, Jean-Charles</style></author><author><style face="normal" font="default" size="100%">Frikke-Schmidt, Ruth</style></author><author><style face="normal" font="default" size="100%">EADB</style></author><author><style face="normal" font="default" size="100%">O. Kilpeläinen, Tuomas</style></author><author><style face="normal" font="default" size="100%">J.F. Loos, Ruth</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Genomics link obesity and type 2 diabetes to Alzheimer’s disease to unveil novel biological insights</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2026.02.10.26344393</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.64898/2026.02.10.26344393</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Body mass index (BMI), type 2 diabetes (T2D) and associated cardiometabolic features modify Alzheimer’s disease (AD) risk, yet shared mechanisms remain poorly understood. Using sex- and age-stratified genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Employing multi-trait, machine learning and single-cell transcriptomics, we identify sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify 35 putative effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping to peripheral immune and metabolic tissues and cell-types. Pathway enrichment identifies druggable targets in calcium and potassium channel signaling. Across 81 approved drugs modulating shared risk genes, levosimendan - a calcium sensitizer for heart failure - inhibits tau oligomerization and emerges as a repurposing candidate. These findings elucidate sex-specific cardiometabolic drivers of AD, identify actionable biological pathways, and reveal drug candidates for AD prevention and treatment.Competing Interest StatementO.A.A. is a consultant to Cortechs.ai and Precision Health, received speaker's honorarium from Lilly, Janssen, Lundbeck, Otsuka. Ruth J.F. Loos has received honoraria for consulting roles from Novo Nordisk and Eli Lilly and Companies.Funding StatementThis work was supported by the Novo Nordisk Foundation (NNF18CC0034900, NNF21SA0072102, and NNF23SA0084103) and PhD fellowship support from the Novo Nordisk Foundation through the Copenhagen Bioscience PhD Programme (NNF0078230). The Novo Nordisk Foundation Center for Basic Metabolic Research (https://cbmr.ku.dk) is an independent research center at the University of Copenhagen, partially funded by an unrestricted donation from the Novo Nordisk Foundation. R.J.F.L. is supported by grants from the National Institutes of Health (NIH) (R01DK107786, R01DK075787, R01DK124097, R01HL156991, U01HG011723, R01DK123019) and the Novo Nordisk Foundation (NNF20OC0059313). T.O.K. is supported by a grant from the Novo Nordisk Foundation (NNF22OC0074128). The work developed by EADB was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Programme Neurodegenerative Disease Research (JPND). Inserm UMR1167 is also funded by Inserm, Institut Pasteur de Lille, the Lille Metropole Communaute Urbaine, the French government LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimers disease). The Bulgarian cohort was partially supported by the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, project BG-RRP-2.004-0004-C01, Strategic research and innovation program for development of Medical university - Sofia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The European Alzheimer and Dementia Biobank Consortium gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.ebi.ac.uk/gwas/studies/GCST90027158 https://www.ebi.ac.uk/gwas/publications/30239722 https://www.ebi.ac.uk/gwas/publications/35551307</style></abstract></record></records></xml>